At the International Psoriasis Council (IPC), we’re a passionate community of researchers and physician experts who share a common goal: improving the health and well-being of people with psoriasis worldwide. We understand the challenges people with psoriasis face and are committed to making a difference.
Our focus is educating health care professionals in psoriasis care management, which aligns with the World Health Organization’s call for improved physician training. We offer clinicians a range of free resources, tools, and information, including live education sessions, webinars, and on-demand videos featuring IPC Board Members and Councilors, renowned opinion leaders in psoriasis.
We are also highly committed to enhancing patient outcomes worldwide by prioritizing research efforts. Our focus is on strengthening the capacity of researchers, promoting collaboration through international partnerships, stakeholder involvement, and evidence-based research, and offering innovative programs and events that support the growth and development of early-career researchers. Together, we can achieve our ultimate goal of improving health care outcomes for all.
IPC was established in 2004 as a United States-based nonprofit organization led by a Board of Directors and supported by a dedicated staff. Our vision is to create a world free of the burden of psoriasis, where people with psoriasis worldwide have access to the best available care and are empowered to lead healthy, fulfilling lives. Our mission is to improve the health and well-being of people with psoriasis and associated diseases worldwide through education, research, and advocacy. We’re excited about the future and look forward to making a positive impact.
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
A new IPC paper in JAAD presents five priorities for improving metabolic screening, advancing GLP-1 research in the context of psoriasis, and defining the dermatologist’s role in managing cardiometabolic risk in psoriasis patients.
IPC Jr. Councilor Mio Nakamura speaks with Dr. John Koo about how personality traits, including borderline personality disorder, shape clinical interactions and shares practical strategies for dermatologists to build stronger patient relationships.
Recordings from the IPC Fellows Research Class #1: Global and Collaborative Research in Psoriasis are now available. Program Chairs Peter van de Kerkhof, MD, PhD, and María Julia Cura, MD, led a faculty of international experts through sessions on unresolved questions in the era of effective psoriasis therapies, building global research collaborations, and connecting psoriasis research across disciplines. Watch to hear from Wolf Henning Boehncke, MD, MA, Christopher Griffiths, OBE, MD, FMedSci, and Georg Stingl, MD, as they share perspectives shaping the next generation of psoriasis research.
The IPC Resource Library now includes a dedicated Research Skills category, bringing together videos, articles, and presentations focused on building stronger research capabilities in psoriasis. Browse the current collection to find resources on topics from collaborative research methods to career development for researchers at every stage.
Rare ADAR1 gene mutations drive a distinct, interferon-fueled psoriasis subtype, and it responds to JAK1 and TYK2 inhibitors rather than standard IL-17/IL-23 biologics.
IPC Councilor Anna Lopez Ferrer, MD, PhD, reviews PURE-4, a four-item tool that helps dermatologists screen psoriasis patients for psoriatic arthritis (PsA) risk. She traces its evolution across three studies (2018–2026) into a validated predictor of early PsA.
IPC Councilor André Lucas Ribeiro, MD, reframes PsA as a slow transition from psoriasis, not a sudden event, opening the door to disease interception. He outlines the steps needed to get there, from harmonizing definitions to reducing inflammatory burden.
